In 1990, the first approved PEG–protein conjugate (PEG–adenosine deaminase, Adagen®) appeared in the market to treat severe combined immunodeficiency caused by an inherited deficiency of the adenosine deaminase enzyme [23]. The gene discussed is ADA; the disease is immunodeficiency disease.